Absci (ABSI) Non-Current Assets (2020 - 2026)
Absci (ABSI) posted Non-Current Assets of $63.6 million for Q1 2026, down 4.65% sequentially from $66.7 million in Q4 2025, and down 16.8% YoY from $76.5 million in Q1 2025.
Absci (ABSI) Non-Current Assets (2020 - 2026) Analysis & Trends
Absci has reported Non-Current Assets for 7 years, with the latest figure at $63.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 16.8% year-over-year to $63.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $272.8 million (down 17.74% YoY) and the FY2025 annual result came in at $66.7 million, down 16.36% from the prior year.
- Non-Current Assets declined to $63.6 million in Q1 2026 per ABSI's latest filing, from $66.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $139.5 million in Q1 2022 and troughed at $63.6 million in Q1 2026.
- A 5-year average of $99.0 million and a median of $93.1 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets retreated 4.32% in 2022, then dropped 28.65% in 2024.
- Over 5 years, Non-Current Assets stood at $134.1 million in 2022, then declined by 27.9% to $96.7 million in 2023, then retreated by 17.52% to $79.8 million in 2024, then fell by 16.36% to $66.7 million in 2025, then slipped by 4.65% to $63.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $63.6 million, $66.7 million, and $70.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | 60.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.65 Mn |
| Mar 31, 2026 | 63.62 Mn |
| Dec 31, 2025 | 66.72 Mn |
| Sep 30, 2025 | 70.00 Mn |
| Jun 30, 2025 | 72.49 Mn |
| Mar 31, 2025 | 76.47 Mn |
| Dec 31, 2024 | 79.78 Mn |
| Sep 30, 2024 | 85.09 Mn |
| Jun 30, 2024 | 90.34 Mn |
| Mar 31, 2024 | 93.10 Mn |
| Dec 31, 2023 | 96.72 Mn |
| Sep 30, 2023 | 101.63 Mn |
| Jun 30, 2023 | 106.12 Mn |
| Mar 31, 2023 | 130.49 Mn |
| Dec 31, 2022 | 134.15 Mn |
| Sep 30, 2022 | 138.01 Mn |
| Jun 30, 2022 | 138.43 Mn |
| Mar 31, 2022 | 139.50 Mn |
| Dec 31, 2021 | 153.12 Mn |
| Sep 30, 2021 | 148.45 Mn |